Victoria Charlotte Simensen
A5007743083- COVID-19 Clinical Research Studies
- Health Systems, Economic Evaluations, Quality of Life
- Long-Term Effects of COVID-19
- Childhood Cancer Survivors' Quality of Life
- Cancer survivorship and care
- Biomedical Ethics and Regulation
- Biomedical and Engineering Education
- Global Cancer Incidence and Screening
- Intensive Care Unit Cognitive Disorders
- Lung Cancer Treatments and Mutations
- Vitamin C and Antioxidants Research
- SARS-CoV-2 and COVID-19 Research
- Healthcare Quality and Management
- Chronic Lymphocytic Leukemia Research
- Clinical practice guidelines implementation
- Economic and Financial Impacts of Cancer
- Advances in Oncology and Radiotherapy
- Pancreatitis Pathology and Treatment
- Phagocytosis and Immune Regulation
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Family Support in Illness
- Health and Medical Research Impacts
- Lymphoma Diagnosis and Treatment
Norwegian Institute of Public Health
2022-2024
Oslo University Hospital
2019-2021
Abstract Background Baricitinib has shown efficacy in hospitalized patients with COVID-19, but no placebo-controlled trials have focused specifically on severe/critical COVID, including vaccinated participants. Methods Bari-SolidAct is a phase-3, multicentre, randomised, double-blind, trial, enrolling participants from June 3, 2021 to March 7, 2022, stopped prematurely for external evidence. Patients COVID-19 were randomised 4 mg once daily or placebo, added standard of care. The primary...
Chronic fatigue (CF), substantial for ≥ six months, can manifest as a late effect (LE) after cancer treatment, and may affect several aspects of life. In Norwegian cohort Hodgkin's lymphoma survivors (HLS), more than decade contemporary risk-adapted treatment regimens with limited use radiotherapy (RT), we assessed: (1) Prevalence of, (2) factors associated (3) implications CF on socioeconomic status (SES) work ability (WA).HLS treated between 1997-2006, aged 8-49 years at diagnosis, were...
Purpose: Lymphoma survivors after high dose therapy with autologous stem cell (HD-ASCT) are at risk for late adverse effects (AEs). Information patients receive and collect throughout their cancer trajectory about diagnosis, treatment schedule risks of AEs may influence attitudes health-related behavior in the years treatment. The purpose this study was to explore level knowledge lymphoma HD-ASCT a median 12 primary diagnosis.Material methods: From national on lymphomas, 269 met an...
Background: The oral, selective Janus kinase 1/2 inhibitor baricitinib has shown efficacy in mixed populations of hospitalised participants with COVID-19. Bari-SolidAct is the first trial investigator-initiated, adaptive platform EU-SolidAct, and a multinational, phase 3, randomised, double-blind, placebo-controlled patients confirmed SARS-CoV-2 infection. We aimed to evaluate safety plus standard care adults severe or critical COVID-19.Methods: study was conducted 39 clinical sites...
Integrated care pathway (ICP) is a prevailing concept in health management including cancer care. Though substantial research has been conducted on ICPs knowledge still deficient explaining how characteristics of diagnose, applied procedures, patient group and organizational context influence specific practicing ICPs. We studied coordination takes place three pathways four Norwegian hospitals. identified core contextual variables affect complexity predictability the performance each pathway....